PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in adeno-associated virus (AAV) gene therapy, today announced a major expansion of its artificial intelligence and machine learning (AI/ML) strategy and the addition of two world-class scientific advisors: Pranam Chatterjee, PhD (University of Pennsylvania) and Philip M. Kim, PhD (University…
Read More
Latus Bio Strengthens Executive Team with Appointments of Ainslie Little as COO and Katie Hewitt as interim CBO BOSTON--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company driving advances in AAV gene therapy, announces the appointments of Ainslie Little, PhD, as COO and Katie Hewitt, as interim CBO. “These appointments reflect…
Read More
Latus Bio Announces Publication of Breakthrough Research on Novel AAV Capsid Variant for Huntington’s and Parkinson’s Disease Gene Therapy PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in tissue-targeted AAV gene therapy, today announces the publication of a seminal research manuscript in Nature Communications: “Optimized AAV capsids for basal…
Read More
Latus Bio Unveils AAV-Ep+ Capsid Variant Capable of Unprecedented Protein Production in the Brain PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced new research published today in Science Translational Medicine, “AAVs engineered for robust brain transduction drive therapeutically relevant expression of secreted recombinant…
Read More
Latus Bio Announces Multiple Oral and Poster Presentations at the Upcoming American Society for Gene and Cell Therapy Annual Meeting PHILADELPHIA--(BUSINESS WIRE)--Latus Bio Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, has announced upcoming oral and poster presentations at the American Society for Gene and Cell Therapy (ASGCT)…
Read More
Latus Bio Announces Data Presentations in Support of its Preclinical Huntington’s Disease Gene Therapy Program PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in AAV gene therapy, is pleased to announce data presentations in support of its preclinical drug candidate at the 20th Annual CHDI Huntington’s Disease (HD) Therapeutics…
Read More